Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score / Ménard, S.; Balsari, A.; Tagliabue, E.; Camerini, T.; Casalini, P.; Bufalino, R.; Castiglioni, F.; Carcangiu, M. L.; Gloghini, A.; Scalone, S.; Querzoli, P.; Lunardi, M.; Molino, A.; Mandarà, M.; Mottolese, M.; Marandino, F.; Venturini, M.; Bighin, C.; Cancello, G.; Montagna, E.; Perrone, F.; De Matteis, A.; Sapino, A.; Donadio, M.; Battelli, N.; Santinelli, Alfredo; Pavesi, L.; Lanza, A.; Zito, F. A.; Labriola, A.; Aiello, R. A.; Caruso, M.; Zanconati, F.; Mustacchi, G.; Barbareschi, M.; Frisinghelli, M.; Russo, R.; Carrillo, G.; Omero, Group. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 19:(2008), pp. 1706-1712.
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.
SANTINELLI, ALFREDO;
2008-01-01
Abstract
Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
